CMS Open Payments · Program Year 2024
Xiros Limited
Xiros Limited reported $2,625.00 across General Payments, Research, and Ownership to 1 physicians and teaching hospitals across 1 transactions.
- $2.6K Below-median payer
- All-tracks total
- 1 Below-median volume
- Transactions
- 1 Below-median reach
- Recipients
- #1772
- of 1,925 companies
Xiros Limited reported $2,625.00 across all CMS Open Payments tracks (General + Research + Ownership) to 1 physicians and teaching hospitals in Program Year 2024 - ranking #1772 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $2,625.00, averaging $2.6K per recipient.
Xiros Limited's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
10/100
Total payments
F
10/100
Transaction volume
F
10/100
Physician reach
F
10/100
Payment type diversity
F
10/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer xiros-limited Xiros Limited
$2.6K · #1772/1,925 · 0.0% industry · PY2024
- TOT $2.6K
- RANK #1772
- SHARE 0.0%
- TXN 1
- RCP 1
- CAT 1
- GEN $2.6K
- TOP1 100.0%
- PY 2024
Volume peers
Nearest volume peer: EDW Pharma, Inc. ($2.6K)
Xiros Limited sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
What the Data Shows for Xiros Limited
Three separate CMS disclosure tracks feed the all-tracks total above - General, Research, and Ownership/Investment - each reported under its own rules and combined here for one comparable figure. For Xiros Limited that figure is drawn almost entirely from the General Payments track (day-to-day consulting, meals, travel and speaking fees). CMS releases each Program Year roughly 12 months after it ends; the methodology page covers the full standardization basis.
Of the 1 general-payment categories charted below, "Consulting Fee" is the largest at $2.6K across 1 transactions, 100.0% of this company's General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
"Consulting Fee" leads Xiros Limited's 1-category general-payment breakdown at $2.6K, 100.0% of the reported total.
How Xiros Limited divides its payments
Top payment categories by total reported dollar volume
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $2.6K | 1 | 100.0% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $2,625.00 (100.0%) of $2,625.00 in this company's General Payments records across 1 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Xiros Limited
The five named recipients with the highest reported General Payments from this company
- 1
Kyle Borque
$2,625.00 across 1 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Xiros Limited ranks #1772 of 1,925 by total payments (bottom 8% by spend) but is notably more concentrated than that alone would suggest -- #130 of 1,838 by HHI (top 7% most concentrated). Its payments land on an unusually narrow set of recipients for its spend size.
View all 12 companies in this HHI neighborhood as a list
- New Wave Endo-Surgical Corp. : $1.2K total payments, HHI 10000
- Ottobock SE & Co. KGaA : $306.0K total payments, HHI 10000
- VoxNeuro USA Inc. : $2.0K total payments, HHI 10000
- Solco Biomedical Co., Ltd. : $50.0K total payments, HHI 10000
- PAVmed Inc. : $2.8K total payments, HHI 10000
- Advanced Instruments, LLC : $3.1K total payments, HHI 10000
- Xiros Limited (this company) : $2.6K total payments, HHI 10000
- Arena Pharmaceuticals, Inc. : $34.1K total payments, HHI 10000
- CraniUS LLC : $379.4K total payments, HHI 10000
- Sebia Inc : $29.09 total payments, HHI 10000
- F&A Foundation, LLC : $27.5K total payments, HHI 10000
- Transcend : $13.4K total payments, HHI 10000
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Xiros Limited's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Xiros Limited.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Xiros Limited.
Showing 6 of 1,924 companies with CMS-reported payment data.
Maquet Critical Care AB
Joline Medical Inc
McKesson Medical-Surgical, Inc.
Spectra Medical Devices, LLC
Kettenbach LP
Put this to use
Xiros Limited ranks #1772 of 1,925 by all-tracks total payments, led by "Consulting Fee".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Consulting Fee" spend across every manufacturer, not just Xiros Limited. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.